Recent Updates
Recently added Catalysts
CLGN Positive Sentiment

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS

Tuesday, August 5, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CollPlant Biotechnologies, a company specializing in regenerative and aesthetics medicine, has announced that it will release its second quarter financial results on August 20, 2025, prior to the U.S. markets opening. The company focuses on developing products using its proprietary rhCollagen technology. It has also entered into a partnership with Allergan for the commercialization of dermal and soft tissue fillers, indicating potential growth in its product offerings.
Price reaction · baseline $2.2479 (2025-08-04 close) · hit after-hours · clean, no other CLGN news in the window
day 0 close
+0.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • CollPlant is advancing innovative technologies in regenerative medicine.
  • Partnership with Allergan enhances potential for product commercialization.
  • Focus on 3D bioprinting aligns with demand for advanced medical solutions.

Full Press Release Details

REHOVOT, Israel, Aug. 5, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the second quarter on Wednesday, August 20, 2025, before the opening of the U.S. financial markets.
CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.
In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information about CollPlant, visit http://www.collplant.com.
Tel: +972-73-2325600
Email: [email protected]
LifeSci Advisors, LLC
Logo: https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg

Frequently Asked Questions

When will CollPlant report its financial results?

CollPlant will report its financial results on August 20, 2025, before U.S. market opening.

What is the focus of CollPlant's technologies?

CollPlant focuses on 3D bioprinting, tissue repair, and medical aesthetics.

What is rhCollagen?

rhCollagen is recombinant human collagen developed using plant-based genetic engineering.

Who is CollPlant partnered with for dermal fillers?

CollPlant partnered with Allergan, an AbbVie company, for dermal and soft tissue fillers.

Where can I find more information about CollPlant?

More information can be found on CollPlant's website at http://www.collplant.com.

ShareAdd on Google
Tags: CLGN Viatris Investor Conferences Healthcare CollPlant Allergan regenerative medicine rhCollagen
Last updated: Aug 5, 2025